Petros pharmaceuticals demonstrates positive results following successful completion of initial cohort of phase 2 equivalent self-selection study for stendra (avanafil) rx-to-otc switch

Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward stendra® working to become the first erectile dysfunction medication to successfully achieve otc status new york, ny / accesswire / january 17, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces the successful completion of the initial cohort of a phase 2 equivalent self-selection study (sss).
PTPI Ratings Summary
PTPI Quant Ranking